Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck

Oral Oncology , 04/19/2012

Gefitinib has clinical activity as monotherapy in squamous cell carcinoma of the head and neck (SCCHN). Dose escalation of gefitinib is feasible and may increase skin toxicity, but the data do not support increased activity.

Print Article Summary